Novartis India introduces Pluvicto, Country’s First Approved Radioligand Therapy for Advanced Prostate Cancer
Novartis India has launched Pluvicto (lutetium-177 vipivotide tetraxetan), marking the introduction of India’s first regulatory-approved radioligand therapy for eligible patients…